From Discovery of Snake Venom Disintegrins to A Safer Therapeutic Antithrombotic Agent
AbstractSnake venoms affect blood coagulation and platelet function in diverse ways. Some venom components inhibit platelet function, while other components induce platelet aggregation. Among the platelet aggregation inhibitors, disintegrins have been recognized as unique and potentially valuable tools for examining cell–matrix and cell–cell interactions and for the development of antithrombotic and antiangiogenic agents according to their anti-adhesive and anti-migration effect on tumor cells and antiangiogenesis activities. Disintegrins represent a family of low molecular weight, cysteine-rich, Arg-Gly-Asp(RGD)/Lys-Gly-Asp(KGD)-containing polypeptides, which inhibit fibrinogen binding to integrin αIIbβ3 (i.e., platelet glycoprotein IIb/IIIa), as well as ligand binding to integrins αvβ3, and α5β1 expressed on cells (i.e., fibroblasts, tumor cells, and endothelial cells). This review focuses on the current efforts attained from studies using disintegrins as a tool in the field of arterial thrombosis, angiogenesis, inflammation, and tumor metastasis, and briefly describes their potential therapeutic applications and side effects in integrin-related diseases. Additionally, novel R(K)GD-containing disintegrin TMV-7 mutants are being designed as safer antithrombotics without causing thrombocytopenia and bleeding. View Full-Text
Share & Cite This Article
Kuo, Y.-J.; Chung, C.-H.; Huang, T.-F. From Discovery of Snake Venom Disintegrins to A Safer Therapeutic Antithrombotic Agent. Toxins 2019, 11, 372.
Kuo Y-J, Chung C-H, Huang T-F. From Discovery of Snake Venom Disintegrins to A Safer Therapeutic Antithrombotic Agent. Toxins. 2019; 11(7):372.Chicago/Turabian Style
Kuo, Yu-Ju; Chung, Ching-Hu; Huang, Tur-Fu. 2019. "From Discovery of Snake Venom Disintegrins to A Safer Therapeutic Antithrombotic Agent." Toxins 11, no. 7: 372.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.